4-氨基-8-氯-2-甲基喹啉 | 68017-48-1

• 物质功能分类: 医药中间体 - 杂环化合物 - 喹啉类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 4-氨基-8-氯-2-甲基喹啉
• 英文名称: 2-Methyl-4-amino-8-chlorchinolin
• 英文别名: 8-chloro-2-methyl-quinolin-4-ylamine；8-Chloro-2-methylquinolin-4-amine
• CAS: 68017-48-1
• 化学式: C₁₀H₉ClN₂
• mdl: MFCD01870546
• 分子量: 192.648
• InChiKey: AUOKCARPGGOSDI-UHFFFAOYSA-N

物化性质

• 熔点：
  210 °C(Solv: benzene (71-43-2))
• 沸点：
  361.4±37.0 °C(Predicted)
• 密度：
  1.307±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  38.9
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  苯基磷二酰胺 、 8-氯-2-甲基-4-羟基喹啉 以50%的产率得到
  参考文献：
  名称：

  MALHOTRA R. C.; RAMACHANDRAN P. K., INDIAN J. CHEM., 1978, B 16, NO 4, 329

  摘要：

  DOI：

文献信息

• PHENYL UREA AND PHENYL THIOUREA DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS
  申请人：SMITHKLINE BEECHAM PLC

  公开号：EP1150977A1

  公开（公告）日：2001-11-07
• Bone Modulators And Methods Therewith
  申请人：Espina Virginia

  公开号：US20120065166A1

  公开（公告）日：2012-03-15

  THE INVENTION RELATES TO compositions, compounds, proteins and methods of treatment therewith. Aspects of embodiments also relate to a method of treating a patient by delivering to the tissues of said patient or administering to said patient a therapeutically effective amount of one or more compounds. Aspects of embodiments also relate to a method of detecting the presence of bone disease by machine-assaying detectable serotonin. Aspects of embodiments also relate to methods of treating disease in subjects.
• US6699879B1
  申请人：——

  公开号：US6699879B1

  公开（公告）日：2004-03-02
• [EN] PHENYL UREA AND PHENYL THIOUREA DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS<br/>[FR] DERIVES DE PHENYLUREE ET DE PHENYLTHIOUREE UTILISES COMME ANTAGONISTES DES RECEPTEURS DE L'OREXINE
  申请人：SMITHKLINE BEECHAM PLC

  公开号：WO2000047577A1

  公开（公告）日：2000-08-17

  The present invention provides phenyl urea and phenyl thiourea derivatives which are non-peptide antagonists of human orexin receptors, in particular orexin-1 receptors, of formula (I) in which: Z represents oxygen or sulfur; and R1 to R7 represent various substituent groups; and pharmaceutically acceptable salts thereof. In particular, these compounds are of potential use in the treatment of obesity including obesity observed in Type 2(non-insulin-dependent) diabetes patients and/or sleep disorders.
• MALHOTRA R. C.; RAMACHANDRAN P. K., INDIAN J. CHEM., 1978, B 16, NO 4, 329
  作者：MALHOTRA R. C.、 RAMACHANDRAN P. K.

  DOI：——

  日期：——